In addition, the FDA-approved HDAC inhibitor panobinostat, induces rapid metabolic reprograming in DLBCL tumour cells with marked changes in choline pathway metabolites for the synthesis of membrane phospholipids [62]. Here, HDAC9 is linked to diffuse large B-cell lymphoma.